Unconfigured Ad

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts
  • yasutake
    Member
    • Sep 2008
    • 11

    Coverage (Velvet)

    Hello, all

    Does anyone know what the coverage means in velvet ?

    According to the manual of velvet, the relation between k-mer coverage Ck and standard (nucleotide-wise) coverage C is Ck = C*(L-k+1)/L.

    Is C calculated as follows ?

    Read length: 36bp
    Number of reads: 50,000,000 X 2 (paired-end)
    Size of reference sequence: 5M

    C = 36bp X 50,000,000 X 2 / 5M = 720

    I'd be happy if anyone answer the question !

    yasutake
  • jnfass
    Member
    • Aug 2008
    • 88

    #2
    Looks right to me ... there are 720 bases in reads for every 1 base in your reference.

    For Ck, the "length" in kmers of your reference is practically the same as length in bases ... (actually, 5M - 36 + 1, which is ~5M for the purposes of the equations below), so if you calculate the number of kmers in every read, it's 36-k+1. If you were to calculate the kmer coverage directly, you'd be asking how many read kmers you have per every reference kmer, so that's:
    (36-k+1)*50M*2 / 5M

    so if you already have base coverage calculated, you multiply by (36-k+1)/36 ... or (L-k+1)/L ... to get from base coverage to kmer coverage.
    Last edited by jnfass; 08-05-2011, 11:33 AM. Reason: clarity

    Comment

    • Torst
      Senior Member
      • Apr 2008
      • 275

      #3
      I'd be happy if anyone answer the question !
      You should consider joining the Velvet mailing list and asking Daniel Zerbino directly:

      Comment

      • yasutake
        Member
        • Sep 2008
        • 11

        #4
        jnfass and Torst,

        Thank you very much for your help !

        yasutake

        Comment

        • panos_ed
          Member
          • May 2010
          • 11

          #5
          Originally posted by jnfass View Post
          so if you already have base coverage calculated, you multiply by (36-k+1)/36 ... or (L-k+1)/L ... to get from base coverage to kmer coverage.
          So Velvet is using k-mer coverage values instead of base coverage in its parameters, right?

          In the above example, if my k-mer size is 21 and I want to eliminate all regions with coverage of 2x or below I shouldn't use '-cov_cutoff 2'. Instead I should use '-cov_cutoff 0.9'... Am I right?

          And what about the '-exp_cov' parameter? Should I use k-mer coverage values for this parameter, too?

          Comment

          • jnfass
            Member
            • Aug 2008
            • 88

            #6
            Originally posted by panos_ed View Post
            So Velvet is using k-mer coverage values instead of base coverage in its parameters, right?

            In the above example, if my k-mer size is 21 and I want to eliminate all regions with coverage of 2x or below I shouldn't use '-cov_cutoff 2'. Instead I should use '-cov_cutoff 0.9'... Am I right?

            And what about the '-exp_cov' parameter? Should I use k-mer coverage values for this parameter, too?
            Yes, on both counts.

            By the way, the -exp_cov value is used to determine which parts of the graph are likely due to repeat sequence ... some multiple (maybe 1.5?? I forget...) of the -exp_cov value serves as the cutoff, and nodes with higher coverage are deemed repeats. Given the wild variation in coverage from the nextGen sequencing technologies, which can be an order of magnitude or more from what I've seen, with Illumina, SOLiD, and 454, you might want to consider increasing -exp_cov above the auto estimate. YMMV, of course.

            ~Joe

            Comment

            • Torst
              Senior Member
              • Apr 2008
              • 275

              #7
              Joe

              Originally posted by jnfass View Post
              Given the wild variation in coverage from the nextGen sequencing technologies, which can be an order of magnitude or more from what I've seen, with Illumina, SOLiD, and 454, you might want to consider increasing -exp_cov above the auto estimate. YMMV, of course.
              Can you clarify what you mean by the above statement in italics?

              ie. are you saying you get 10-fold difference in coverage of NON-repeated elements??

              Comment

              Latest Articles

              Collapse

              • SEQadmin2
                Proteomic Platforms: How to Choose the Right Analytical Strategy to Improve Detection and Clinical Applications
                by SEQadmin2


                Proteomics platforms are evolving rapidly, with advances in mass spectrometry and affinity-based approaches expanding what researchers can detect and at what scale. As the field moves toward deeper proteome coverage and clinical applications, scientists face an increasingly complex landscape of tools. This article will explore how researchers are navigating these choices to find the right platform for their work.

                The systematic characterization of the human proteome has
                ...
                Yesterday, 11:48 AM
              • SEQadmin2
                Advanced Sequencing Platforms Tackle Neuroscience’s Toughest Genomics Problems
                by SEQadmin2



                Genomics studies in neuroscience face a special challenge due to the brain’s complexity and scarcity of samples. Mapping changes in cell type and state using conventional next-generation sequencing methods remains challenging. Advances in technologies like single-cell sequencing, spatial transcriptomics, and long-read sequencing have opened the door to deeper studies of the brain and diseases like Alzheimer’s, amyotrophic lateral sclerosis (ALS), and schizophrenia.
                ...
                07-09-2026, 11:10 AM
              • SEQadmin2
                Cancer Drug Resistance: The Lingering Barrier to Rising Survival
                by SEQadmin2



                Cancer survival rates have significantly increased in the last few decades in the United States, reaching a combined 70% 5-year survival rate by 2021. Behind this number, there are years of research to find new therapies, drug targets, and early detection methods. But there is one core challenge that keeps slowing down these advances, and it’s about drug resistance.

                There is no single reason why many patients don’t respond to treatment as expected. Cancer is...
                07-08-2026, 05:17 AM

              ad_right_rmr

              Collapse

              News

              Collapse

              Topics Statistics Last Post
              Started by SEQadmin2, Yesterday, 11:10 AM
              0 responses
              9 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-13-2026, 10:26 AM
              0 responses
              30 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-09-2026, 10:04 AM
              0 responses
              39 views
              0 reactions
              Last Post SEQadmin2  
              Started by SEQadmin2, 07-08-2026, 10:08 AM
              0 responses
              25 views
              0 reactions
              Last Post SEQadmin2  
              Working...